Zura Bio Ltd.

ZURA

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001855644


None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $113.9M
Warnings	dilution, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Mar 19, 2026 244 days before the rescan; latest periodic filing 10-Q received Oct 27, 2026
Last close	$1.03 2026-11-17; market equity $99.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with significant unmet medical need. These diseases are often chronic, biologically complex and difficult to treat, and many patients do not achieve durable disease control with currently available therapies. Our strategy is to identify immune-mediated diseases in which translational and clinical evidence supports the role of specific biological pathways in disease pathogenesis.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 73.5						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(2.6%)	(6.7%)		73.5	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 21.9						
Altman Z double-prime	3.48	0.31		24.3	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	9.05x	2.68x		19.5	781	2025-12-31
Growth and financing, sleeve percentile 36.6						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	33.9%				
NOPAT must exceed $100,000						
Asset growth, three years	178.7%	3.2%		0.8	663	2025-12-31
Net share issuance, one year	38.8%	1.6%		72.4	625	2026-03-16

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 38.8%
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	8.3%	(1.7%)	55
Distance from 52-week high	(85.3%)	(30.5%)	7
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(65.1%)	0.5%	11
Book value to price	1.78	0.28	93
Sales to price	not computable	0.36	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(0.09)	(0.19)	55
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$187.7M
Operating cash flow, four quarters	-$64.8M
Months of runway	34.7
Days since last periodic filing	22 (10-Q received Oct 27, 2026)
Median daily dollar volume, 63 sessions	$9.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$68.7M	2025-12-31	2026-03-19	10-K	26-032080
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$64.8M	2025-12-31	2026-03-19	10-K	26-032080
3	assets	us-gaap:Assets	$113.9M	2025-12-31	2026-03-19	10-K	26-032080
4	assets	us-gaap:Assets	$179.5M	2024-12-31	2026-03-19	10-K	26-032080
5	current assets	us-gaap:AssetsCurrent	$112.3M	2025-12-31	2026-03-19	10-K	26-032080
6	current liabilities	us-gaap:LiabilitiesCurrent	$12.4M	2025-12-31	2026-03-19	10-K	26-032080
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$224.5M	2025-12-31	2026-03-19	10-K	26-032080
8	operating income	us-gaap:OperatingIncomeLoss	-$75.2M	2025-12-31	2026-03-19	10-K	26-032080
9	book equity	us-gaap:StockholdersEquity	$101.5M	2025-12-31	2026-03-19	10-K	26-032080
10	liabilities	us-gaap:Liabilities	$12.4M	2025-12-31	2026-03-19	10-K	26-032080
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$75,000	2024-12-31	2026-03-19	10-K	26-032080
12	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$9,000	2024-12-31	2026-03-19	10-K	26-032080
13	operating income	us-gaap:OperatingIncomeLoss	-$55.2M	2024-12-31	2026-03-19	10-K	26-032080
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$52.4M	2024-12-31	2026-03-19	10-K	26-032080
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2024-12-31	2025-03-25	10-K	25-000443
16	current assets	us-gaap:AssetsCurrent	$178.7M	2024-12-31	2026-03-19	10-K	26-032080
17	current liabilities	us-gaap:LiabilitiesCurrent	$19.5M	2024-12-31	2026-03-19	10-K	26-032080
18	current assets	us-gaap:AssetsCurrent	$100.8M	2023-12-31	2025-03-25	10-K	25-000443
19	current liabilities	us-gaap:LiabilitiesCurrent	$20.3M	2023-12-31	2025-03-25	10-K	25-000443
20	assets	us-gaap:Assets	$100.8M	2023-12-31	2025-03-25	10-K	25-000443
21	assets	us-gaap:Assets	$5.3M	2022-12-31	2024-03-28	10-K	24-000329
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	94,880,710	2026-03-16	2026-03-19	10-K	26-032080
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	68,374,998	2025-03-21	2025-03-25	10-K	25-000443

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.